

# Summary of Contents

## Volume 1

- Chapter 1. History, Introduction and Short Title
- Chapter 2. Interpretation
- Chapter 3. Her Majesty
- Chapter 4. Patent Office and Officers
- Chapter 5. Rules and Regulations
- Chapter 6. Seal; Proof of Patents
- Chapter 7. Patent Agents
- Chapter 8. Appeals
- Chapter 9. Use of Patents by Government; Government Owned Patents
- Chapter 10. Use of Patents for International Humanitarian Purposes to Address Public Health Problems
- Chapter 11. Nuclear Energy; General; Duties of Commissioner
- Chapter 12. Application for Patents; Joint Applications
- Chapter 13. Improvements, Filing of Prior Art, Examination and Divisional Applications
- Chapter 14. Biological Materials
- Chapter 15. Patents: Refusal, Grant, form and Term, Reissue
- Chapter 16. Disclaimers and Re-examination
- Chapter 17. Transfers
- Chapter 18. Legal Proceedings in Respect of Patents
- Chapter 19. Infringement

## Volume 2

- Chapter 19. Infringement (Continued)
- Chapter 20. Impeachment, Judgments and Conditions
- Chapter 21. Abandonment and Reinstatement of

Applications; Offences and Punishments;  
Written Demands and Miscellaneous Matters

- Chapter 22. Transitional Provisions
- Chapter 23. Patented or Protected Medicines
- Chapter 24. Supplementary Protection for Inventions—  
Medicinal Ingredients
- Chapter 25. Schedules to the Patent Act
- Chapter 26. Repealed Provisions

**Appendices**

- Appendix A. Patent Rules [Repealed], SOR/96-423
- Appendix B. Patent Rules, SOR/2019-251
- Appendix C. Public Servants Inventions Act

**Appendix D. Patented Medicines (Notice of Compliance)  
Regulations**

- Appendix D1. Patented Medicines (Notice of Compliance)  
Regulations, SOR/93-133
- Appendix D2. P.C. 2011-453 March 25, 2011 and Regulatory  
Impact Analysis Statement
- Appendix D3. P.C. 2010-1249 October 7, 201 and  
Regulatory Impact Analysis Statement
- Appendix D4. P.C. 2008-1090 June 12, 2008 and Regulatory  
Impact Analysis Statement
- Appendix D5. P.C. 2006-1077 October 5, 2006 and  
Regulatory Impact Analysis Statement
- Appendix D6. P.C. 1998-366 12 March, 1998 and Regulatory  
Impact Analysis Statement
- Appendix D7. Regulatory Impact Analysis Statement, SOR/  
93-133
- Appendix D8. Regulatory Impact Analysis Statement, SOR/  
2017-166
- Appendix D9. Guidance Document: Patented Medicines  
(Notice of Compliance) Regulations
- Appendix D10. Case and Trial Management Guidelines for  
Complex Proceedings and Proceedings under  
the *PM(NOC) Regulations*
- Appendix E. Use of Patented Products for International  
Humanitarian Purposes Regulations

## SUMMARY OF CONTENTS

- Appendix F. Patented Medicines Regulations
- Appendix G. Certificate of Supplementary Protection Regulations
- Appendix H. Patented Medicine Prices Review Board Rules of Practice and Procedure
- Appendix I. Patented Medicine Prices Review Board Compendium of Policies, Guidelines and Procedures

### **Appendix J. Patented Medicine Prices Review Board Guidelines 2019**

- Appendix J1. Draft Guidelines Consultation 2019
- Appendix J2. Patented Medicine Prices Review Board Guidelines 2019
- Appendix K. Canadian Intellectual Property Office Practice Notices

### **Appendix L. Quantum Tables**

- Appendix L1. Quantum Table—Remedies for Patent Infringement

## **Volume 3**

### **Appendices (Continued)**

#### **Appendix L. Quantum Tables (Continued)**

- Appendix L1. Quantum Table—Remedies for Patent Infringement (Continued)
- Appendix L2. Quantum Table Damages Pursuant to Section 8 of the Patented Medicines (Notice of Compliance) Regulations
- Appendix L.50. College of Patent Agents and Trademark Agents
- Appendix M. Patent Law Treaty
- Appendix N. Patent Cooperation Treaty
- Appendix O. Regulations under the Patent Cooperation Treaty
- Appendix O.1. Administrative Instructions Under the Patent Cooperation Treaty
- Appendix P. PCT Applicant's Guide (International Phase)

|                                     |   |
|-------------------------------------|---|
| Appendix Q.                         | PCT Applicant's Guide (National Chapter—CA)   |
| Appendix R.                         | Current Developments                          |
| Appendix S.                         | Canada-United States-Mexico Agreement (CUSMA) |
| Appendix T.                         | Legal Memos                                   |
| Appendix U.                         | Manual of Patent Office Practice              |
| <b>Appendix V. CIPO Patent Fees</b> |   |
| Appendix V1.                        | Patent Fees                                   |
| Appendix V2.                        | Methods of Payment Accepted                   |
| <b>Table of Cases</b>               |   |
| <b>Index</b>                        |   |

# **Table of Contents**

## **Volume 1**

### **CHAPTER 1. HISTORY, INTRODUCTION AND SHORT TITLE**

#### **I. HISTORY AND INTRODUCTION**

- § 1:1 Amendment History
- § 1:2 Introduction

#### **II. SHORT TITLE**

- § 1:3 [Section 1 Short Title]
- § 1:4 History, Policy and Legislative Jurisdiction
- § 1:5 Interpretation
- § 1:6 —“Old Act” and “New Act”
- § 1:7 —Judicial Review
- § 1:8 Interplay between Patent Law and Competition Law

### **CHAPTER 2. INTERPRETATION**

#### **I. SECTION 2 TEXT; INTERPRETATION AND DEFINITIONS**

- § 2:1 [Section 2 Definitions]
- § 2:2 Interpretation and Definitions

#### **II. PART ONE—MAJOR DEFINITIONS**

##### **A. “APPLICANT”**

- § 2:3 General
- § 2:4 Inventor
- § 2:5 Inventorship vs. Invention
- § 2:6 When Is an Invention Made?
- § 2:7 Inventorship Contrasted with Verification by Others

##### **B. “INVENTION”**

- § 2:8 Inventive Ingenuity

- § 2:9 Statutory Requirements of an Invention—Novelty, Utility, Non-Obviousness
- § 2:10 Invention vs. Discovery
- § 2:11 Statutory Definition
- § 2:12 “Art”
- § 2:13 “Manufacture”; “Composition of Matter”

### C. SUBJECT-MATTER

- § 2:14 General
- § 2:15 Natural Phenomena, Laws of Nature, Scientific Principles
- § 2:16 Combinations and Aggregations
- § 2:17 Business Systems and Methods; Professional Skills and Methods
- § 2:18 Computer-Related Subject-Matter
- § 2:19 Methods of Medical Treatment
- § 2:20 Various Biotechnological Developments
- § 2:21 Printed Matter Producing Only an Artistic, Intellectual or Literary Result
- § 2:22 Mere Human Conduct or Mental Steps and Apparatus for Implementing Same
- § 2:23 Architectural Plans
- § 2:24 New Uses of Known Subject-Matter
- § 2:25 New Advantages of Known Compounds—Selection Inventions
- § 2:26 Substitutions as Distinct from Selections
- § 2:27 Size of the Prior Class
- § 2:28 Double Patenting
- § 2:29 Disclosure
- § 2:30 Verification Revisited in the Selection Context

## III. PART TWO—TERMS REQUIRING DEFINITION

### A. UTILITY

- § 2:31 General
- § 2:32 Utility and Disclosure
- § 2:33 Roadmap
- § 2:34 Tactical and Patent Drafting Considerations
- § 2:35 Utility Analysis Looks at the Patent as a Whole
- § 2:36 Utility Is Assessed Across the Scope of a Claim
- § 2:37 Date for Assessing Utility
- § 2:38 Relevant Date Is Canadian Filing Date
- § 2:39 Commercial Success

## TABLE OF CONTENTS

- § 2:40 Control
- § 2:41 Disclosure of Utility in the Patent

### B. SOUND PREDICTION

- § 2:42 General
- § 2:43 Policy
- § 2:44 Establishing Facts Necessary to Apply the Doctrine of Sound Prediction
- § 2:45 Testing Contrasted with “Safety and Efficacy”
- § 2:46 Disclosure Requirement
- § 2:47 Soundness of the Prediction
- § 2:48 Standard of Proof
- § 2:49 Sound Prediction and Obviousness Distinguished
- § 2:50 Date for Assessing the Sound Prediction—Historical
- § 2:51 —Current

### C. “PROMISE OF THE PATENT”

- § 2:52 Promise Doctrine Is Not the Correct Approach to Assess Utility
- § 2:53 The Aftermath of Astrazeneca
- § 2:54 Post-Esomeprazole Test for Determining Utility

### D. TABLE OF UTILITY—SOUND PREDICTION CASES

- § 2:55 Note
- § 2:56 Hoffmann-La Roche Limited v. Sandoz Canada Inc.
- § 2:57 Swist v. Meg Energy Corp.
- § 2:58 Teva Canada Innovation v. Pharmascience Inc.
- § 2:59 Les Laboratoires Servier v. Apotex Inc.
- § 2:60 Janssen Inc. v. Apotex Inc.
- § 2:61 Western Oilfield Equipment Rentals Ltd. v. M-I LLC
- § 2:62 Safe Gaming System v. Atlantic Lottery Corporation
- § 2:63 Gilead Sciences, Inc. v. Idenix Pharmaceuticals Inc.
- § 2:64 Astrazeneca Canada Inc. v. Apotex Inc.
- § 2:65 Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research
- § 2:66 Regents of the University of California v. I-MED Pharma Inc.
- § 2:67 Pfizer Canada Inc. v. Teva Canada Limited
- § 2:68 Pfizer Canada Inc. v. Apotex Inc.
- § 2:69 Packers Plus Energy Services Inc. v. Essential Energy Services Ltd.

- § 2:70 Bristol-Myers Squibb Canada v. Apotex Inc.
- § 2:71 Leo Pharma Inc. v. Teva Canada Ltd.
- § 2:72 Mediatube Corp. v. Bell Canada
- § 2:73 Meda AB v. Canada (Minister of Health)
- § 2:74 Excalibre Oil Tools Ltd. v. Advantage Products Inc.
- § 2:75 Eli Lilly Canada Inc. v. Hospira Healthcare Corp.
- § 2:76 Allergan Inc. v. Apotex Inc.
- § 2:77 Gilead Sciences, Inc. v. Canada (Minister of Health)
- § 2:78 Novartis Pharmaceuticals Canada Inc. v. Teva Canada Ltd.
- § 2:79 Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC
- § 2:80 Allergan Inc. v. Canada (Minister of Health)
- § 2:81 Cobalt Pharmaceuticals Co. v. Bayer Inc.
- § 2:82 Laboratoires Servier v. Canada (Minister of Health)
- § 2:83 Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC
- § 2:84 Alcon Canada Inc. v. Apotex Inc.
- § 2:85 Astrazeneca Canada Inc. v. Apotex Inc.
- § 2:86 Actavis Pharma Co. v. Alcon Canada Inc.
- § 2:87 Alcon Canada Inc. v. Apotex Inc.
- § 2:88 Pfizer Canada Inc. v. Mylan Pharmaceuticals ULC
- § 2:89 Astrazeneca Canada Inc. v. Pharmascience Inc.
- § 2:90 Allergan Inc. v. Canada (Minister of Health)
- § 2:91 Pfizer Canada Inc. v. Apotex Inc.
- § 2:92 Alcon Canada Inc. v. Cobalt Pharmaceuticals Co.
- § 2:93 Eurocopter c. Bell Helicopter Textron Canada Ltée
- § 2:94 Apotex Inc. v. Sanofi-Aventis Canada Inc.
- § 2:95 Teva Canada Ltd. v. Novartis AG
- § 2:96 Apotex Inc. v. H. Lundbeck A/S
- § 2:97 Pfizer Canada Inc. v. Pharmascience Inc.
- § 2:98 Pfizer Canada Inc. v. Novopharm Ltd.
- § 2:99 Pfizer Canada Inc. v. Mylan Pharmaceuticals ULC
- § 2:100 Astrazeneca Canada Inc. v. Mylan Pharmaceuticals ULC
- § 2:101 Allergan Inc. v. Canada (Minister of Health)
- § 2:102 Eli Lilly Canada Inc. v. Novopharm Ltd.
- § 2:103 Sanofi-Aventis Canada Inc. v. Apotex Inc.
- § 2:104 Pfizer Canada Inc. v. Canada (Minister of Health)
- § 2:105 Novopharm Ltd. v. Eli Lilly & Co.
- § 2:106 Pfizer Canada Inc. v. Canada (Minister of Health)
- § 2:107 Glaxosmithkline Inc. v. Pharmascience Inc.
- § 2:108 Apotex Inc. v. Merck & Co.



## TABLE OF CONTENTS

- § 2:109 Lundbeck Canada Inc. v. Canada (Minister of Health)
- § 2:110 Laboratoires Servier v. Apotex Inc.
- § 2:111 Eli Lilly Canada Inc. v. Apotex Inc.

## **IV. PART THREE—LIST OF REMAINING DEFINITIONS**

- § 2:112 “Claim Date”
- § 2:113 “Certificate of Supplementary Protection”
- § 2:114 “Country”
- § 2:115 “Filing Date”
- § 2:116 “Holder”
- § 2:117 “Legal Representatives”
- § 2:118 “Patent”
- § 2:119 “Patentee”
- § 2:120 “Predecessor in Title”
- § 2:121 “Prescribed”
- § 2:122 “Priority Date” [Repealed Definition—See Repealed Provisions]
- § 2:123 “Request for Priority”

## **CHAPTER 3. HER MAJESTY**

- § 3:1 [Section 2.1 Binding on Her Majesty]
- § 3:2 Binding Effect on Government

## **CHAPTER 4. PATENT OFFICE AND OFFICERS**

- § 4:1 [Section 3 Patent Office]
- § 4:2 [Section 4 Commissioner of Patents]
- § 4:3 Section 4 Commentary
- § 4:4 [Section 5 Assistant Commissioner]
- § 4:5 [Section 6 Staff]
- § 4:6 Section 6 Commentary
- § 4:7 [Section 7 Officers of Patent Office Not to Deal in Patents]
- § 4:8 [Section 8 Clerical Errors—Repealed]
- § 4:9 Section 8 Commentary
- § 4:10 [Section 8.1 Electronic Form and Means]
- § 4:11 Section 8.1 Commentary
- § 4:12 [Section 8.2 Repealed]
- § 4:13 Section 8.2 Commentary
- § 4:14 [Section 9 Destroyed or Lost Patents]
- § 4:15 [Section 10 Inspection by the Public]

- § 4:16 Section 10 Commentary
- § 4:17 [Section 11 Patents Issued Out of  
Canada—Repealed]
- § 4:18 Section 11 Commentary

## **CHAPTER 5. RULES AND REGULATIONS**

- § 5:1 [Section 12 Rules and Regulations]
- § 5:2 Section 12 Commentary
- § 5:3 Section 12(1)(i)
- § 5:4 Patent Cooperation Treaty
- § 5:5 Time Limits under Pct—Rectification of Procedural  
Errors
- § 5:6 Section 12(1)(j.8)

## **CHAPTER 6. SEAL; PROOF OF PATENTS**

- § 6:1 [Section 13 Seal of Office]
- § 6:2 [Section 14 Certified Copies of Patents as Evidence]

## **CHAPTER 7. PATENT AGENTS**

- § 7:1 [Section 15 Repealed]
- § 7:2 Section 15 Commentary
- § 7:3 [Section 16 Misconduct]
- § 7:4 [Section 16.1 Privileged Communication]

## **CHAPTER 8. APPEALS**

- § 8:1 [Section 17 Practice on Appeals]
- § 8:2 [Section 18 Notice on Appeal]
- § 8:3 Section 18 Commentary

## **CHAPTER 9. USE OF PATENTS BY GOVERNMENT; GOVERNMENT OWNED PATENTS**

### **I. USE OF PATENTS BY GOVERNMENT**

- § 9:1 [Section 19 Government May Apply to Use Patented  
Invention]
- § 9:2 Section 19 Commentary
- § 9:3 [Section 19.1 Conditions for Authorizing Use]
- § 9:4 Section 19.1 Commentary
- § 9:5 [Section 19.2 Appeal]
- § 9:6 Section 19.2 Commentary
- § 9:7 [Section 19.3 Regulations]

## TABLE OF CONTENTS

- § 9:8 Section 19.3 Commentary
- § 9:9 [Section 19.4 Application by Minister]

## II. GOVERNMENT OWNED PATENTS

- § 9:10 [Section 20 Assignment to Minister of National Defence]
- § 9:11 [Section 21 Agreement between Canada and Other Government]

## CHAPTER 10. USE OF PATENTS FOR INTERNATIONAL HUMANITARIAN PURPOSES TO ADDRESS PUBLIC HEALTH PROBLEMS

- § 10:1 [Section 21.01 Purpose]
- § 10:2 Section 21.01 Commentary
- § 10:3 [Section 21.02 Definitions]
- § 10:4 Section 21.02 Commentary
- § 10:5 [Section 21.03 Amending Schedules]
- § 10:6 Section 21.03 Commentary
- § 10:7 [Section 21.04 Authorization]
- § 10:8 [Section 21.05 Form and Content of Authorization]
- § 10:9 [Section 21.06 Disclosure of Information on Website]
- § 10:10 [Section 21.07 Export Notice]
- § 10:11 [Section 21.08 Royalty]
- § 10:12 [Section 21.09 Duration]
- § 10:13 [Section 21.1 Use Is Non-Exclusive]
- § 10:14 [Section 21.11 Authorization Is Non-Transferrable]
- § 10:15 [Section 21.12 Renewal]
- § 10:16 [Section 21.13 Termination]
- § 10:17 [Section 21.14 Termination by Federal Court]
- § 10:18 [Section 21.15 Notice to Patentee]
- § 10:19 [Section 21.16 Obligation to Provide Copy of Agreement]
- § 10:20 [Section 21.17 Application when Agreement Is Commercial in Nature]
- § 10:21 [Section 21.18 Advisory Committee]
- § 10:22 Section 21.18 Commentary
- § 10:23 [Section 21.19 Website for Indices to Canada]
- § 10:24 [Section 21.2 Review]

## **CHAPTER 11. NUCLEAR ENERGY; GENERAL; DUTIES OF COMMISSIONER**

### **I. PATENTS RELATING TO NUCLEAR ENERGY**

- § 11:1 [Section 22 Communication to Canadian Nuclear  
Safety Commission]
- § 11:2 Section 22 Commentary

### **II. GENERAL**

- § 11:3 [Section 23 Patented Invention in Vessels, Aircraft,  
Etc., of Any Country]
- § 11:4 [Section 24 [Repealed]]
- § 11:5 [Section 25 Cost of Proceedings Before the Court]

### **III. DUTIES OF COMMISSIONER**

- § 11:6 [Section 26 Annual Report]
- § 11:7 [Section 26.1 Publication of List of Patents]

## **CHAPTER 12. APPLICATION FOR PATENTS; JOINT APPLICATIONS**

### **I. COMMISSIONER MAY GRANT PATENTS**

#### **A. TEXT OF SECTION 27; INTRODUCTION**

- § 12:1 [Section 27 Commissioner May Grant Patents]
- § 12:2 Introduction

#### **B. SECTION 27(1)**

##### **1. Overview**

- § 12:3 General
- § 12:4 “A Patent for an Invention”
- § 12:5 Unity of Invention

##### **2. Double Patenting**

- § 12:6 General
- § 12:7 Same-Type and Obviousness-Type Double  
Patenting
- § 12:8 Farbwerke
- § 12:9 Agripat
- § 12:10 Shell Oil
- § 12:11 Process Versus Compound Claims

## TABLE OF CONTENTS

|         |  |
|---------|--|
| § 12:12 | Forced Divisionals Do Not Constitute Double Patenting                        |
| § 12:13 | Conterminous Versus Same Invention   |
| § 12:14 | “Same Invention” in Other Contexts   |
| § 12:15 | Obviousness Type Double Patenting  |
| § 12:16 | Focus on Double Patenting Is on the Claims                                   |
| § 12:17 | Two-Way Double Patenting   |
| § 12:18 | Different Inventions, Different Inventors                                    |
| § 12:19 | The ‘Sin’ of Double Patenting  |
| § 12:20 | Dedication to Avoid Double Patenting   |
| § 12:21 | Double Patenting in Selection Patent Context                                 |
| § 12:22 | Obviousness and Obviousness-Type Double Patenting Distinguished              |
| § 12:23 | Double Patenting: Take-Away Points   |
| § 12:24 | Double Patenting in the Patent Office  |
| § 12:25 | Federal Court of Appeal Clarifies Test for Obviousness-Type Double Patenting |
|         | <b>3. Inventorship</b>   |
| § 12:26 | Overview   |
|         | <b>C. SECTION 27(2)</b>  |
| § 12:27 | General  |
|         | <b>D. SECTION 27(3)-(5)—DESCRIPTION AND CLAIMING OF INVENTIONS</b>           |
|         | <b>1. Overview</b>   |
| § 12:28 | General  |
| § 12:29 | History and Policy   |
| § 12:30 | Patent Bargain   |
| § 12:31 | Good Faith   |
|         | <b>2. Duty of Court to Construe Specification</b>                            |
| § 12:32 | Construction Is a Question of Law  |
| § 12:33 | Overpromise Doctrine   |
| § 12:34 | Construction Is to Be Done First   |
| § 12:35 | Infringement Is an Issue of Fact   |
| § 12:36 | Experts Must Be Objective  |
| § 12:37 | Expert Evidence  |
| § 12:38 | Ultimate Issue   |
| § 12:39 | When Are the Claims Construed?   |
|         | <b>3. Specification Directed to Person Skilled in the Art</b>                |
| § 12:40 | General  |

- § 12:41 Posita
- § 12:42 Perspective of Skilled Person
- § 12:43 Posita May Be a Composite
- § 12:44 Common General Knowledge

#### 4. Date as of Which Specification Speaks

- § 12:45 Date of Publication
- § 12:46 Historical
- § 12:47 Potential Issues in Selecting Publication Date for Construction

#### 5. Rules of Construction—Specification

- § 12:48 General
- § 12:49 Evidence of Inventor Irrelevant
- § 12:50 Historical Guidelines
- § 12:51 Benevolent Construction
- § 12:52 Interpretation Act
- § 12:53 Drawings May Be Used in Construction
- § 12:54 Role of the Title
- § 12:55 Role of the Abstract

### E. SECTION 27(3)

#### 1. Duty of Disclosure

- § 12:56 General
- § 12:57 Claim by Claim
- § 12:58 Limits to the Duty to Disclose
- § 12:59 Disclosure: Utility
- § 12:60 Data of Utility in the Patent

#### 2. Insufficiency of Disclosure

- § 12:61 General
- § 12:62 What Is the Invention? How Does It Work?
- § 12:63 Date for Determination
- § 12:64 Insufficiency: Claim by Claim
- § 12:65 Common General Knowledge Can Be Inferred
- § 12:66 Some Experimentation Permitted
- § 12:67 Insufficiency in Computer Software Cases
- § 12:68 How It Works Not Why It Works
- § 12:69 Reliability of Data Not Generally Open to Attack
- § 12:70 Disclosure: Sound Prediction
- § 12:71 AZT Revisited

#### 3. Disclosure in Selection Patents

- § 12:72 General

## TABLE OF CONTENTS

|          |   |
|----------|---|
| § 12:73  | Variants and Improvements                               |
|          | 4. Overlap of Insufficiency and Ambiguity               |
| § 12:74  | General   |
| § 12:75  | Ambiguity and Obscurity Are to Be Avoided               |
| § 12:76  | Difficulty in Understanding Is Not Enough               |
|          | 5. Ambiguity in the Claims                              |
| § 12:77  | General   |
| § 12:78  | Contra Proferentem                                      |
| § 12:79  | Multiple Meanings Not Fatal                             |
| § 12:80  | Obvious Errors Not Fatal                                |
| § 12:81  | Wordsmithing Is Not an Exact Science                    |
| § 12:82  | “Comprising” and the Like                               |
| § 12:83  | About   |
| § 12:84  | Obvious Chemical Equivalent                             |
| § 12:85  | Substantially   |
| § 12:86  | Multiple Modes Distinguished                            |
| § 12:87  | Multiple Measurements May Not Matter                    |
| § 12:88  | Disclosure of Advantages                                |
|          | 6. Best Mode  |
| § 12:89  | General   |
| F.       | SECTION 27(4)—CLAIMS: RULES OF CONSTRUCTION             |
|          | 1. General  |
| § 12:90  | Overview  |
| § 12:91  | Comity and Stare Decisis                                |
| § 12:92  | Claim Construction Comes First                          |
| § 12:93  | Essential to See Where the Shoe Pinches                 |
| § 12:94  | Construing Claims                                       |
| § 12:95  | Purposive Construction                                  |
| § 12:96  | Some Exceptions to Classical Construction               |
| § 12:97  | Ditch the Dictionary                                    |
| § 12:98  | Benevolent Construction                                 |
| § 12:99  | Contra Proferentem                                      |
| § 12:100 | The Court May Not Re-Write the Claims                   |
| § 12:101 | Preamble  |
|          | 2. Purposive Construction: Essential Elements of Claims |
| § 12:102 | Overview  |
| § 12:103 | The Improver Tests                                      |

§ 12:104 Essential Elements: Combinations

3. Resort to Description

§ 12:105 General

4. Comparison with Other Claims

§ 12:106 Claim Differentiation

5. Extrinsic Evidence

§ 12:107 General

§ 12:108 Prosecution Histories/File Wrappers

§ 12:109 Some Uses of File Histories Permitted

6. Claim Style

§ 12:110 General

§ 12:111 Swiss-Style Claims

§ 12:112 Markush Claims

7. Product and Apparatus Claims

§ 12:113 Product Claims

§ 12:114 Apparatus Claims

8. Support by and Conformity with Disclosure

§ 12:115 General

9. Breadth of Claims

§ 12:116 General

§ 12:117 Gillette Defence

10. Consistory Clause in Specification

§ 12:118 General

G. SECTION 27(5)—ALTERNATIVES IN CLAIMS

§ 12:119 General

H. SECTION 27(8)—SCIENTIFIC PRINCIPLE OR  
ABSTRACT THEOREM

§ 12:120 General

I. WORDS AND PHRASES IN PATENTS AND  
PATENT LAW

§ 12:121 27:2720



## TABLE OF CONTENTS

### **II. REFERENCE TO PREVIOUSLY FILED APPLICATION**

- § 12:122 [Section 27.01 Reference to Previously Filed Application]

### **III. MAINTENANCE FEES—PATENT APPLICATIONS**

- § 12:123 [Section 27.1 Maintenance Fees]
- § 12:124 Section 27.1 Commentary

### **IV. FILING DATE**

- § 12:125 [Section 28 Filing Date]
- § 12:126 Section 28(1)
- § 12:127 Section 28(2)

### **V. ADDITIONS**

- § 12:128 [Section 28.01 Addition to Specification or Addition of Drawing to Application]

### **VI. CLAIM DATE**

- § 12:129 [Section 28.1 Claim Date]
- § 12:130 General
- § 12:131 Does the Patent Claim Improper Priority?

### **VII. NOVELTY**

#### **A. GENERAL**

- § 12:132 [Section 28.2 Subject-Matter of Claim Must Not Be Previously Disclosed]
- § 12:133 Overview
- § 12:134 Novelty Assessed on Claim-by-Claim Basis as of the Claim Date
- § 12:135 “Subject-Matter”

#### **B. NOVELTY AND ANTICIPATION: COMPETING CONCEPTS**

- § 12:136 Framework
- § 12:137 Introduction
- § 12:138 Historical: Anticipation and Overclaiming
- § 12:139 Anticipation/Overclaiming Dichotomy Explained
- § 12:140 “Old Act” and “New Act” Tests

## C. HISTORICAL; “OLD ACT” AND PRE-SANOFI SYNTHELABO LAW OF ANTICIPATION

- § 12:141 Anticipation by Prior Disclosure
- § 12:142 Anticipation: General Principles—Mixed Question  
of Law and Fact
- § 12:143 Burden of Proof of Anticipation—General
- § 12:144 —Anticipation Is Difficult to Make Out
- § 12:145 —Paper Patents
- § 12:146 —Evidence: Dating a Prior Publication
- § 12:147 Acts Constituting Anticipation by Prior Disclosure
- § 12:148 Tests for Anticipation
- § 12:149 —Reeves Brothers Tests
- § 12:150 Anticipation by Prior Publication
- § 12:151 —“That Gives Me What I Wish”
- § 12:152 —Mosaic of Documents Prohibited
- § 12:153 —One Disclosure May Be Enough
- § 12:154 Changes to the Law Effected by s. 28.2

## D. ANTICIPATION AS CLARIFIED IN SANOFI

- § 12:155 General
- § 12:156 Trial and Error
- § 12:157 Undue Burden
- § 12:158 Availability to the Public: Issues Left Open by  
Sanofi
- § 12:159 —Recipe Cases
- § 12:160 —Inherency
- § 12:161 Anticipation by Prior Public Use or Sale
- § 12:162 Anticipation and Obviousness—Which Is Assessed  
First?
- § 12:163 —Anticipation vs. Obviousness
- § 12:164 Overclaiming
- § 12:165 Novelty of Particular Types of Invention
- § 12:166 Novelty in Selection Patents
- § 12:167 Authority of Foreign Case Law
- § 12:168 Material Facts Required to Plead Disclosure

## VIII. OBVIOUSNESS

### A. GENERAL

- § 12:169 [Section 28.3 Invention Must Not Be Obvious]
- § 12:170 Overview
- § 12:171 Obviousness in “Old Act” and “New Act” Patents

## TABLE OF CONTENTS

### B. THE RELEVANT DATE TO ASK THE QUESTION

- § 12:172 General
- § 12:173 New Act Patents
- § 12:174 Old Act Patents
- § 12:175 Date of Invention
- § 12:176 A Question of Fact
- § 12:177 The Test for Obviousness
- § 12:178 Evolution of the Test for Obviousness
- § 12:179 Cripps Question
- § 12:180 The “Classic” Beloit Test: “Directly and Without Difficulty”
- § 12:181 Moving Towards a Principled and Objective Approach
- § 12:182 Sanofi-Synthelabo Test—A Structured Approach

### C. THE NOTIONAL “PERSON SKILLED IN THE ART”

- § 12:183 General
- § 12:184 Qualities and Characteristics of the Posita
- § 12:185 Experts and Inventors Are Not Posita
- § 12:186 Difference between Posita in England and Canada

### D. THE COMMON GENERAL KNOWLEDGE OF THE PERSON SKILLED IN THE ART

- § 12:187 General
- § 12:188 What Constitutes Common General Knowledge
- § 12:189 Proving the Existence of Common General Knowledge
- § 12:190 Mosaicing
- § 12:191 Prior Art from Foreign Jurisdictions
- § 12:192 Unpublished Work
- § 12:193 Evidence of Prior Public Use
- § 12:194 The Prior Art Is Not Static
- § 12:195 Prejudice
- § 12:196 Post-Relevant Date Publications
- § 12:197 The Posita Is Expected to Keep Up with Advances
- § 12:198 Experts Should Conduct Prior Art Search

### E. INVENTIVE CONCEPT

- § 12:199 General

- § 12:200 What Constitutes Invention
- § 12:201 Different Stages at Which Invention May Be Found
- § 12:202 Invention in the Idea or Application of the Idea or Both

## F. INVENTIVE STEP

- § 12:203 General
- § 12:204 Routine Effort
- § 12:205 Mere Scintilla of Invention
- § 12:206 Simplicity
- § 12:207 Unexpected Utility
- § 12:208 Selection
- § 12:209 Analogous Use of a Well-Known Principle
- § 12:210 New Compounds

## G. “WORTH A TRY”; “OBVIOUS TO TRY”

- § 12:211 General
- § 12:212 “Worth a Try” Not the Test in Canada
- § 12:213 Experimentation
- § 12:214 Untested Hypotheses
- § 12:215 “Worth a Try” under UK Law Not Equivalent to “Obvious to Try” under U.S. Law
- § 12:216 “Obvious to Try” Must Be Approached Cautiously
- § 12:217 Court of Appeal Confirming “Obvious to Try” Is the Test in Canada
- § 12:218 Cases Where “Obvious to Try” Does Not Apply
- § 12:219 Motivation

## H. SECONDARY CONSIDERATIONS

- § 12:220 General
- § 12:221 Commercial Success
- § 12:222 Non-Technical Factors
- § 12:223 Commercial Acquiescence
- § 12:224 Imitation by Others
- § 12:225 Evidence Highly Skilled Persons Did Not Arrive at Invention
- § 12:226 Receipt of Award/Failure by Others
- § 12:227 Long Felt Need
- § 12:228 Following a Well-Charted Route
- § 12:229 Prior Art “Teaching Away” from the Invention
- § 12:230 Simultaneous Invention

## I. EVIDENCE RELATING TO OBVIOUSNESS

- § 12:231 Expert Evidence

## TABLE OF CONTENTS

§ 12:232 Inventor Evidence

### J. TECHNICAL CONSIDERATIONS IN ASSESSING OBVIOUSNESS

§ 12:233 Relationship between Obviousness and Anticipation

§ 12:234 Burden of Proof

### K. THE WRONG TESTS

§ 12:235 Ex Post Facto Analysis, Hindsight, Etc.

§ 12:236 Dissection of Combinations

### L. COMPARATIVE VIEWS OF FOREIGN TESTS FOR OBVIOUSNESS

§ 12:237 European Test

§ 12:238 British Test

§ 12:239 Australian Test

§ 12:240 Comparison between Canadian, U.K. and U.S. Tests

### M. TABLE OF OBVIOUSNESS CASES (POST-SANOFI-SYNTHELABO)

§ 12:241 Guest Tek Interactive Entertainment Ltd. v. Nomadix, Inc.

§ 12:242 dTechs EPM Ltd. v. British Columbia Hydro and Power Authority

§ 12:243 Apotex Inc. v. Shire LLC

§ 12:244 Western Oilfield Equipment Rentals Ltd. v. M-I LLC

§ 12:245 Betser-Zilevitch v. Petrochina Canada Ltd.

§ 12:246 Janssen Inc. v. Apotex Inc.

§ 12:247 Bristol-Myers Squibb Canada Co. v. Pharmascience Inc.

§ 12:248 Swist v. Meg Energy Corp.

§ 12:249 Teva Canada Innovation v. Pharmascience Inc.

§ 12:250 Amgen Inc. v. Pfizer Canada ULC

§ 12:251 Bauer Hockey Ltd. v. Sport Maska Inc. (CCM Hockey)

§ 12:252 Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research

§ 12:253 Georgetown Rail Equipment Company v. Rail Radar Inc.

§ 12:254 Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC

- § 12:255 Eli Lilly Canada Inc. v. Apotex Inc.
- § 12:256 Teva Canada Limited v. Janssen Inc.
- § 12:257 Apotex Inc. v. Pfizer Canada Inc.
- § 12:258 Packers Plus Energy Services Inc. v. Essential Energy Services Ltd.
- § 12:259 Tearlab Corporation v. I-Med Pharma Inc.
- § 12:260 Arctic Cat, Inc. v. Bombardier Recreational Products Inc.
- § 12:261 Bombardier Recreational Products Inc. v. Arctic Cat, Inc.
- § 12:262 AFD Petroleum Ltd. v. Frac Shack Inc.
- § 12:263 Teva Canada Limited v. Pfizer Canada Inc.
- § 12:264 Tetra Tech EBA Inc. v. Georgetown Rail Equipment Company
- § 12:265 Ciba Specialty Chemicals Water Treatments Limited v. SNF Inc.
- § 12:266 Bristol-Myers Squibb Canada Co. v. Apotex Inc.
- § 12:267 Astrazeneca Canada Inc. v. Mylan Pharmaceuticals ULC
- § 12:268 Mediatube Corp. v. Bell Canada
- § 12:269 Frac Shack Inc. v. Afd Petroleum Ltd.
- § 12:270 Janssen Inc. v. Actavis Pharma Co.
- § 12:271 Meda AB v. Canada (Minister of Health)
- § 12:272 Bayer Inc. v. Cobalt Pharmaceuticals Co.
- § 12:273 Arctic Cat Inc. v. Bombardier Recreational Products Inc.
- § 12:274 Gilead Sciences, Inc. v. Canada (Minister of Health)
- § 12:275 Gilead Sciences, Inc. v. Canada (Minister of Health)
- § 12:276 Pollard Banknote Ltd. v. BABN Technologies Corp.
- § 12:277 Allergan Inc. v. Apotex Inc.
- § 12:278 Bristol-Myers Squibb Canada Co. v. Teva Canada Ltd.
- § 12:279 Excalibre Oil Tools Ltd. v. Advantage Products Inc.
- § 12:280 Uponor AB v. Heatlink Group Inc.
- § 12:281 Alcon Canada Inc. v. Actavis Pharma Co.
- § 12:282 E. Mishan & Sons, Inc. v. Supertek Canada Inc.
- § 12:283 Leo Pharma Inc. v. Teva Canada Ltd.
- § 12:284 Eli Lilly Canada Inc. v. Apotex Inc.
- § 12:285 Zero Spill Systems (Int'l) Inc. v. Heide
- § 12:286 Cobalt Pharmaceuticals Co. v. Bayer Inc.
- § 12:287 Janssen Inc. v. Teva Canada Ltd.

## TABLE OF CONTENTS

|          |   |
|----------|---|
| § 12:288 | Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC                      |
| § 12:289 | Janssen Inc. v. Teva Canada Ltd.  |
| § 12:290 | Laboratoires Servier v. Canada (Minister of Health)                     |
| § 12:291 | Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC                      |
| § 12:292 | Dow Chemical Co. v. Nova Chemicals Corp.                                |
| § 12:293 | Astrazeneca Canada Inc. v. Apotex Inc.                                  |
| § 12:294 | Alcon Canada Inc. v. Cobalt Pharmaceuticals Co.                         |
| § 12:295 | Varco Canada Limited v. Pason Systems Corp.                             |
| § 12:296 | Sanofi-Aventis v. Apotex Inc.   |
| § 12:297 | Zero Spill Systems (Int'l) v. 614248 Alberta Ltd (cob Lea-Der Coatings) |
| § 12:298 | Hoffman[*]-La Roche Limited v. Apotex Inc.                              |
| § 12:299 | Astrazeneca Canada Inc. v. Ranbaxy Pharmaceuticals Canada Inc.          |
| § 12:300 | Novartis Pharmaceuticals Canada Inc. v. Teva Canada Limited             |
| § 12:301 | Apotex Inc. v. H. Lundbeck A/S  |
| § 12:302 | Pfizer Canada Inc. v. Pharmascience Inc.                                |
| § 12:303 | Wenzel Downhole Tools Ltd. v. National-Oilwell Canada Ltd.              |
| § 12:304 | Allergan Inc. v. Canada (Minister of Health)                            |
| § 12:305 | Astrazeneca Canada Inc. v. Pharmascience Inc.                           |
| § 12:306 | Bristol-Myers Squibb Canada Co. v. Mylan Pharmaceuticals ULC            |
| § 12:307 | Fournier Pharma Inc. v. Canada (Minister of Health)                     |
| § 12:308 | Fournier Pharma Inc. v. Canada (Minister of Health)                     |
| § 12:309 | Eurocopter v. Bell Helicopter Textron Canada Ltée                       |
| § 12:310 | Allergan Inc. v. Canada (Minister of Health)                            |
| § 12:311 | Astrazeneca Canada Inc. v. Mylan Pharmaceuticals ULC                    |
| § 12:312 | Weatherford Canada Ltd. v. Corlac Inc.                                  |
| § 12:313 | Hoffmann-La Roche Ltd. v. Apotex Inc.                                   |
| § 12:314 | Bauer Hockey Corp. v. Easton Sports Canada Inc.                         |
| § 12:315 | Glaxosmithkline Inc. v. Pharmascience Inc.                              |
| § 12:316 | Lundbeck Canada Inc. v. Canada (Minister of Health)                     |
| § 12:317 | Eli Lilly Canada Inc. v. Apotex Inc.                                    |
| § 12:318 | Merck & Co. v. Canada (Minister of Health)                              |
| § 12:319 | Merck-Frosst-Schering Pharma GP v. Canada (Minister of Health)          |

- § 12:320 Novopharm Ltd. v. Eli Lilly and Co.
- § 12:321 Novo Nordisk Canada Inc. v. Cobalt Pharmaceuticals Inc.
- § 12:322 Ratiopharm Inc. v. Pfizer Ltd.
- § 12:323 Eli Lilly Canada Inc. v. Novopharm Ltd.
- § 12:324 Bridgeview Manufacturing Inc. v. 931409 Alberta Ltd.
- § 12:325 Astrazeneca Canada Inc. v. Apotex Inc.
- § 12:326 Abbott Laboratories v. Canada (Minister of Health)
- § 12:327 Pfizer Canada Inc. v. Ratiopharm Inc.
- § 12:328 Merck & Co. v. Pharmascience Inc.
- § 12:329 Pfizer Canada Inc. v. Canada (Minister of Health)
- § 12:330 Sanofi-Aventis Canada Inc. v. Ratiopharm Inc.
- § 12:331 Blair v. Canada (Attorney General)
- § 12:332 Biovail Corp. v. Canada (Minister of Health)
- § 12:333 Schering-Plough Canada Inc. v. Pharmascience Inc.
- § 12:334 Pfizer Canada Inc. v. Canada (Minister of Health)
- § 12:335 Pfizer Canada Inc. v. Canada (Minister of Health)
- § 12:336 Lundbeck Canada Inc. v. Ratiopharm Inc.
- § 12:337 Sanofi-Aventis Canada Inc. v. Hospira Healthcare Corp.
- § 12:338 Eli Lilly and Co. v. Apotex Inc.
- § 12:339 Purdue Pharma v. Pharmascience Inc.
- § 12:340 Laboratories Servier v. Apotex Inc.
- § 12:341 Sanofi-Aventis Canada Inc. v. Apotex Inc.
- § 12:342 Pfizer Canada Inc. v. Novopharm Ltd.
- § 12:343 Eli Lilly Canada Inc. v. Novopharm Ltd.
- § 12:344 Eli Lilly Canada Inc. v. Novopharm Ltd.
- § 12:345 Hershkovitz v. Tyco Safety Products Canada Ltd.
- § 12:346 Uview Ultraviolet Systems Inc. v. Brasscorp Ltd. (c.o.b. Cliplight Manufacturing Co.)
- § 12:347 Bristol-Myers Squibb Canada Co. v. Apotex Inc.
- § 12:348 Pfizer Canada Inc. v. Apotex Inc.
- § 12:349 Abbott Laboratories v. Canada (Minister of Health)

## N. POST-SANOFI PATENT APPEAL BOARD DECISIONS—OBVIOUSNESS

- § 12:350 Amylin Pharmaceuticals, Inc. No. 2356706
- § 12:351 Société Des Produits Nestlé S.A. Patent Application No. 2,223,198
- § 12:352 Borowski Patent Application No. 2,365,923 (Re)



## TABLE OF CONTENTS

|          |   |
|----------|---|
| § 12:353 | Rpx Corp. Application No. 2,222,229 (Re)                            |
| § 12:354 | Pitney Bowes Inc. Patent Application No. 2,285,834 (Re)             |
| § 12:355 | Progressive Casualty Insurance Co. Application No. 2,344,781 (Re)   |
| § 12:356 | Pitney Bowes Inc. Application No. 2,306,540 (Re)                    |
| § 12:357 | Navigation Technologies Corp. Patent Application No. 2,195,252 (Re) |
| § 12:358 | Oncolytics Biotech, Inc. Patent Application No. 2,388,807 (Re)      |
| § 12:359 | Toyota Jidosha Kabushiki Kaisha Patent App. No. 2,206,896 (Re)      |
| § 12:360 | Blair Patent Application No. 2,286,794 (Re)                         |
| § 12:361 | Symtron Systems, Inc. Patent Application No. 2,050,365 (Re)         |
| § 12:362 | Avaya Technology Corp. Patent Application No. 2,454,966 (Re)        |
| § 12:363 | Pitney Bowes Inc. Patent Application No. 2,397,287 (Re)             |
| § 12:364 | Delcath Systems, Inc. Patent Application No. 2,264,559 (Re)         |
| § 12:365 | Pitney Bowes Inc. Patent Application No. 2,292,065 (Re)             |

## **IX. REQUEST FOR PRIORITY**

|          |                                     |
|----------|-------------------------------------|
| § 12:366 | [Section 28.4 Request for Priority] |
| § 12:367 | General                             |
| § 12:368 | The Paris Convention                |

## **X. NON-RESIDENT APPLICANTS [REPEALED]**

|          |                   |
|----------|-------------------|
| § 12:369 | [29, 30 Repealed] |
|----------|-------------------|

## **XI. JOINT APPLICATIONS**

|          |   |
|----------|---|
| § 12:370 | [Section 31 Effect of Refusal of a Joint Inventor to Proceed] |
| § 12:371 | Erroneous Identification of Inventors                         |
| § 12:372 | Co-ownership of Patents                                       |

## **CHAPTER 13. IMPROVEMENTS, FILING OF PRIOR ART, EXAMINATION AND DIVISIONAL APPLICATIONS**

### **I. IMPROVEMENTS**

|        |                           |
|--------|---------------------------|
| § 13:1 | [Section 32 Improvements] |
|--------|---------------------------|

- § 13:2 General
- § 13:3 [Sections 33, 34 [Repealed]]

## **II. FILING OF PRIOR ART**

- § 13:4 [Section 34.1 Filing]
- § 13:5 General

## **III. EXAMINATION**

- § 13:6 [Section 35 Request for Examination]
- § 13:7 General
- § 13:8 The Examination Process

## **IV. DIVISIONAL APPLICATIONS**

- § 13:9 [Section 36 Patent for One Invention Only]
- § 13:10 Section 36 Commentary

## **CHAPTER 14. BIOLOGICAL MATERIALS**

- § 14:1 [Section 37 Repealed]
- § 14:2 Section 37 Commentary
- § 14:3 [Section 38 Repealed]
- § 14:4 Section 38 Commentary
- § 14:5 [Section 38.1 Biological Materials May Be Deposited]
- § 14:6 Section 38.1 Commentary
- § 14:7 [Section 38.2 Amendments to Specifications and Drawings]
- § 14:8 Section 38.2 Commentary
- § 14:9 [Section 39 [Repealed]]
- § 14:10 Compulsory Licensing—Pharmaceutical Compositions
- § 14:11 [Section 39.1 to 39.26 [Repealed]]

## **CHAPTER 15. PATENTS: REFUSAL, GRANT, FORM AND TERM, REISSUE**

### **I. REFUSAL OF PATENTS**

- § 15:1 [Section 40 Refusal by Commissioner]
- § 15:2 Section 40 Commentary
- § 15:3 [Section 41 Appeal to Federal Court]
- § 15:4 Section 41 Commentary

### **II. GRANT OF PATENTS**

- § 15:5 [Section 42 Contents of Patents]

## TABLE OF CONTENTS

§ 15:6 Section 42 Commentary

### III. FORM AND TERM OF PATENTS

§ 15:7 [Section 43 Form and Duration of Patents]

§ 15:8 General

§ 15:9 Burden of Proof—Validity of Patent

§ 15:10 [Section 44 Term of Patents Based on Applications  
Filed on or After October 1, 1989]

§ 15:11 Section 44 Commentary

§ 15:12 [Section 45 Term of Patents Based on Applications  
Filed Before October 1, 1989]

§ 15:13 Section 45 Commentary

§ 15:14 [Section 46 Maintenance Fees]

§ 15:15 Section 46 Commentary

### IV. REISSUE OF PATENTS

§ 15:16 [Section 47 Issue of New or Amended Patents]

§ 15:17 Section 47 Commentary

## CHAPTER 16. DISCLAIMERS AND RE-EXAMINATION

### I. DISCLAIMERS

§ 16:1 [Section 48 Patentee May Disclaim Anything  
Included in Patent by Mistake]

§ 16:2 Section 48 Commentary

§ 16:3 Section 48(1)

§ 16:4 Section 48(2) and (3)

§ 16:5 Section 48(4)

§ 16:6 Section 48(6)

§ 16:7 Dedication to the Public: an Alternative to  
Disclaimer

### II. RE-EXAMINATION

#### A. REQUEST FOR RE-EXAMINATION

§ 16:8 [Section 48.1 Request for Re-Examination]

§ 16:9 Section 48.1 Commentary

#### B. RE-EXAMINATION BOARD

§ 16:10 [Section 48.2 Establishment of Re-Examination  
Board]

- § 16:11 Section 48.2 Commentary
- § 16:12 [Section 48.3 Re-Examination Proceeding]
- § 16:13 [Section 48.4 Certificate of Board]
- § 16:14 [Section 48.5 Appeals]
- § 16:15 Section 48.5 Commentary

## **CHAPTER 17. TRANSFERS**

### **I. [HEADING AMENDED 2014, C. 39, S. 134.]**

- § 17:1 [Section 49 Patent, Application and Right or Interest in Invention]
- § 17:2 Section 49 Commentary
- § 17:3 [Section 50 Repealed]
- § 17:4 Section 50 Commentary
- § 17:5 [Section 51 Repealed]
- § 17:6 Section 51 Commentary
- § 17:7 [Section 52 Jurisdiction of Federal Court]
- § 17:8 Variation of Patent Office Records

### **II. STANDARD-ESSENTIAL PATENTS**

- § 17:9 [Section 52.1 Subsequent Patentee or Holder Bound]
- § 17:10 [Section 52.2 Regulations]

## **CHAPTER 18. LEGAL PROCEEDINGS IN RESPECT OF PATENTS**

- § 18:1 [Section 53 Void in Certain Cases, or Valid Only for Parts]
- § 18:2 General
- § 18:3 Error in Material Allegation in Petition
- § 18:4 [Section 53.1 Admissible in Evidence]
- § 18:5 General

## **CHAPTER 19. INFRINGEMENT**

### **I. JURISDICTION OF COURTS**

- § 19:1 [Section 54 Jurisdiction of Courts]
- § 19:2 General
- § 19:3 Policy
- § 19:4 Jurisdiction
- § 19:5 Exemptions from Infringement
- § 19:6 Place of Infringement

## TABLE OF CONTENTS

|         |   |
|---------|---|
| § 19:7  | Construction of Claims  |
| § 19:8  | Infringement Analysis   |
| § 19:9  | Doctrine of Equivalents: Historical and Comparative             |
| § 19:10 | Infringement Analysis Governed by Purposive Construction        |
| § 19:11 | Essential and Non-Essential Elements                            |
| § 19:12 | The “Improver” Questions as Assisting Essentiality Analysis     |
| § 19:13 | Limiting Scope of Claims to Expressed Elements                  |
| § 19:14 | Meaning of “Equivalent” in Infringement Analysis                |
| § 19:15 | Reverse Equivalence   |
| § 19:16 | Analysis of Defendant’s Impugned Article                        |
| § 19:17 | Infringement by Use   |
| § 19:18 | Use as an Intermediate  |
| § 19:19 | Defendant’s Intention   |
| § 19:20 | Contributory Infringement; Related Topics                       |
| § 19:21 | Other Instances of Liability for Incomplete Act of Infringement |
| § 19:22 | Process Claim Infringement by Selling Product                   |
| § 19:23 | Offers to Sell  |
| § 19:24 | Exhaustion of Patent Rights                                     |
| § 19:25 | Threatened Infringement; Threats                                |
| § 19:26 | Defences  |

## II. LIABILITY FOR PATENT INFRINGEMENT

|         |  |
|---------|--|
| § 19:27 | [Section 55 Liability for Patent Infringement]       |
| § 19:28 | Jurisdiction   |
| § 19:29 | —Accrual of Cause of Action; Threatened Infringement |
| § 19:30 | Parties—Plaintiff                                    |
| § 19:31 | —Defendants  |
| § 19:32 | —Liability of Related Entities                       |
| § 19:33 | —Section 55(3)                                       |
| § 19:34 | Pleadings  |
| § 19:35 | Burden of Proof                                      |
| § 19:36 | Defences   |
| § 19:37 | —“Gillette Defence”                                  |
| § 19:38 | Evidence   |
| § 19:39 | Summary Judgment                                     |
| § 19:40 | Interlocutory and Post-Judgment Proceedings          |
| § 19:41 | Remedies   |
| § 19:42 | —Effect of TRIPS on Remedies                         |
| § 19:43 | —Damages   |

- § 19:44 —Accounting of Profits
- § 19:45 —Interest
- § 19:46 —Injunctions; Delivery Up
- § 19:47 —Stay of Execution
- § 19:48 Section 55(2)—Reasonable Compensation for Pre-Grant Use of Invention
- § 19:49 Appeals

### **III. LIMITATION**

- § 19:50 [Section 55.01 Limitation]
- § 19:51 Section 55.01 Commentary

### **IV. BURDEN OF PROOF FOR PATENTED PROCESS**

- § 19:52 [Section 55.1 Burden of Proof for Patented Process]
- § 19:53 Reverse Burden of Proof

### **V. EXCEPTION—THIRD PARTY RIGHTS**

- § 19:54 [Section 55.11 Exception—Third Party Rights]

### **VI. EXCEPTION**

#### **A. GENERAL**

- § 19:55 [Section 55.2 Exception]
- § 19:56 Experimental and Regulatory Use Exception
- § 19:57 History of Legislation and Regulations
- § 19:58 Change in Legislative Landscape
- § 19:59 Authority to Regulate
- § 19:60 Authority to Adopt the PMNOC Regulations

#### **B. RELATIONSHIP TO THE DRUG APPROVAL REVIEW PROCESS**

- § 19:61 General
- § 19:62 Drug Regulatory Process: a Basic Primer
- § 19:63 Drug Submissions
- § 19:64 Safety and Efficacy
- § 19:65 Drug Submissions: Paper Record

## **Volume 2**

- § 19:66 NDS vs. ANDS
- § 19:67 Supplemental Submissions: SNDSs and SANDSs

## TABLE OF CONTENTS

- § 19:68 “Submissions” under the PMNOC Regulations
- § 19:69 Other Changes to Submissions
- § 19:70 Conclusion of Regulatory Review Process
- § 19:71 Confidentiality
- § 19:72 Sponsor of an NDS

### C. PMNOC REGULATIONS

- § 19:73 PMNOC Regulations: Step-by-Step
- § 19:74 Background and History

### D. AMENDMENTS TO THE PMNOC REGULATIONS

- § 19:75 General
- § 19:76 1993 Regulations
- § 19:77 1998 Amendments
- § 19:78 1999 Amendments
- § 19:79 Discussion of 1999 Amendments
- § 19:80 2006 Amendments
- § 19:81 Discussion of 2006 Amendments
- § 19:82 2008 Amendments
- § 19:83 Discussion of 2008 Amendments

### E. INTERPRETING THE PMNOC REGULATIONS

- § 19:84 Approach to Interpretation
- § 19:85 Matters of Interpretation
- § 19:86 “Patented Invention”
- § 19:87 Other Interpretive Aids

### F. JURISPRUDENCE: GENERAL SCHEME AND PURPOSE OF SECTION 55.2 AND RELATED REGULATIONS

- § 19:88 General Scheme

### G. SECTION 3: PATENT REGISTER

- § 19:89 General
- § 19:90 Minister’s Decision Are Amenable to Review in Limited Circumstances
- § 19:91 Judicial Review: Standing

### H. SECTION 4: PATENT LISTS AND PATENT LISTING

- § 19:92 General

- § 19:93 Transitional Provisions
- § 19:94 Process Claims
- § 19:95 Claims to Intermediates
- § 19:96 Use of Intermediates
- § 19:97 Current Three-Step Analysis to Question of Proper Listing
- § 19:98 Single Claim May Suffice
- § 19:99 De-Listing Patents
- § 19:100 When Pre-Amendment Requirements Apply, the Question of Listability Is Whether That Patent Includes a “Claim to the Medicine Itself” or a “Claim for the Use of the Medicine”
- § 19:101 Discussion of Pre-Amendment Listability Requirements
- § 19:102 The Time to Bring an Improper Listing Concern Is in an Application (Either s. 6(5) or at the Hearing)
- § 19:103 Timing

## I. SECTION 5: WHEN ALLEGATIONS TO BE MADE

- § 19:104 General
- § 19:105 Timing of NOAs Vis-à-Vis NDSs
- § 19:106 Multiple and Successive NOAs
- § 19:107 Contents of NOA
- § 19:108 Bald Allegations Are Not Enough
- § 19:109 Sufficiency of the NOA

## J. SECTION 6: PROCEEDINGS FOR AN ORDER OF PROHIBITION

- § 19:110 General
- § 19:111 Minister’s Duties Are Administrative
- § 19:112 Parties
- § 19:113 Interveners
- § 19:114 Procedural Considerations
- § 19:115 Legal Standard: “Justified”
- § 19:116 Standard of Proof
- § 19:117 Burden of Proof
- § 19:118 Overriding Principle
- § 19:119 Burden of Proof as to Allegations of Non-Infringement
- § 19:120 Burden of Proof as to Allegations of Validity
- § 19:121 Historical Overview
- § 19:122 Current View



## TABLE OF CONTENTS

|          |   |
|----------|---|
| § 19:123 | The Burden Matters in “Close Calls”       |
| § 19:124 | Motion to Dismiss Prohibition Proceedings |
| § 19:125 | Section 6(5)(a)                           |
| § 19:126 | Section 6(5)(b)                           |
| § 19:127 | Abuse of Process                          |
| § 19:128 | Issue Estoppel                            |
| § 19:129 | Comity                                    |
| § 19:130 | Motion for Production                     |
| § 19:131 | Presumptions                              |
| § 19:132 | Infringement Issues                       |
| § 19:133 | Use of Disclaimers                        |
| § 19:134 | Effect of Patent Licences                 |

### K. SECTION 7

|          |                             |
|----------|-----------------------------|
| § 19:135 | General                     |
| § 19:136 | Mootness: Withdrawal of NOA |
| § 19:137 | Mootness: Appeals           |

### L. SECTION 8 DAMAGES

|          |  |
|----------|--|
| § 19:138 | General  |
| § 19:139 | Entitlement to Damages: Effect of Declaration of<br>Invalidity/Impeachment |
| § 19:140 | Defences/Factors in Determining Quantum                                    |
| § 19:141 | Moot Appeals and Proceedings   |

### M. MISCELLANY

|          |  |
|----------|--|
| § 19:142 | General  |
| § 19:143 | Interplay with s. 56   |
| § 19:144 | Section 55.2(4) and (5)  |
| § 19:145 | Section 55.2(5)  |
| § 19:146 | Section 55.2(6): Experimental Use Exemption<br>from Infringement |

## VII. EXCEPTION—EXPERIMENTATION

|          |                           |
|----------|---------------------------|
| § 19:147 | Exception—Experimentation |
|----------|---------------------------|

## VIII. ACQUIRED RIGHTS TO USE AND SELL

|          |   |
|----------|---|
| § 19:148 | [Section 56 Patent Not to Affect Previous<br>Purchaser] |
| § 19:149 | Prior Acquisition of Invention                          |

## IX. INJUNCTION MAY ISSUE

|          |                                   |
|----------|-----------------------------------|
| § 19:150 | [Section 57 Injunction May Issue] |
|----------|-----------------------------------|

- § 19:151 Injunctions
- § 19:152 Interlocutory Injunctions
- § 19:153 Laches and Acquiescence
- § 19:154 Accounting of Profits

## **X. INVALID CLAIMS NOT TO AFFECT VALID CLAIMS**

- § 19:155 [Section 58 Invalid Claims Not to Affect Valid Claims]
- § 19:156 General

## **XI. DEFENCE**

- § 19:157 [Section 59 Defence]
- § 19:158 Invalidity as Defence to Patent Infringement

## **CHAPTER 20. IMPEACHMENT, JUDGMENTS AND CONDITIONS**

### **I. IMPEACHMENT**

- § 20:1 [Section 60 Impeachment of Patents or Claims]
- § 20:2 General
- § 20:3 “Interested Person”
- § 20:4 Licensee Estoppel
- § 20:5 Grounds of Invalidity
- § 20:6 Disconformity
- § 20:7 Section 60(3)
- § 20:8 [Section 61 [Repealed]]

### **II. JUDGMENTS**

- § 20:9 [Section 62 Judgment Voiding Patent [Repealed]]
- § 20:10 Section 62 Commentary
- § 20:11 [Section 63 Appeal]
- § 20:12 Section 63 Commentary

### **III. CONDITIONS**

- § 20:13 [Section 64 [Repealed]]
- § 20:14 [Section 65 Abuse of Rights under Patents]
- § 20:15 Section 65 Commentary
- § 20:16 [Section 66 Powers of Commissioner in Cases of Abuse]
- § 20:17 General

## TABLE OF CONTENTS

|         |   |
|---------|---|
| § 20:18 | Section 66(1)(d)                              |
| § 20:19 | Section 66(4)(c)                              |
| § 20:20 | [Section 67 [Repealed]]                       |
| § 20:21 | [Section 68 Contents of Applications]         |
| § 20:22 | Section 68 Commentary                         |
| § 20:23 | [Section 69 Opposition and Counter Statement] |
| § 20:24 | [Section 70 Licence Deemed to Be by Deed]     |
| § 20:25 | Section 70 Commentary                         |
| § 20:26 | [Section 71 Appeal to Federal Court]          |
| § 20:27 | Section 71 Commentary                         |
| § 20:28 | [Section 72 [Repealed]]                       |

## **CHAPTER 21. ABANDONMENT AND REINSTATEMENT OF APPLICATIONS; OFFENCES AND PUNISHMENTS; WRITTEN DEMANDS AND MISCELLANEOUS MATTERS**

### **I. ABANDONMENT AND REINSTATEMENT OF APPLICATIONS**

|        |   |
|--------|---|
| § 21:1 | [Section 73 Deemed Abandonment of Applications] |
| § 21:2 | Section 73 Commentary                           |
| § 21:3 | [Section 73.1 Patent Not Invalid]               |

### **II. OFFENCES AND PUNISHMENT**

|        |   |
|--------|---|
| § 21:4 | [Section 74 [Repealed]]                                 |
| § 21:5 | [Section 75 Offences]                                   |
| § 21:6 | Section 75 Commentary                                   |
| § 21:7 | [Section 76 False Representatives, False Entries, Etc.] |
| § 21:8 | Section 76 Commentary                                   |
| § 21:9 | [Section 76.1 Offence Respecting Patented Medicines]    |

### **III. WRITTEN DEMANDS**

|         |                             |
|---------|-----------------------------|
| § 21:10 | [Section 76.2 Requirements] |
| § 21:11 | [Section 76.3 Regulations]  |

### **IV. MISCELLANEOUS MATTERS**

|         |   |
|---------|---|
| § 21:12 | [Section 77 [Repealed]]                 |
| § 21:13 | [Section 78 Time Limit Deemed Extended] |

## **CHAPTER 22. TRANSITIONAL PROVISIONS**

- § 22:1 [Section 78.1 Definition of “Coming-into-Force Date”]
- § 22:2 Section 78.1 Commentary
- § 22:3 [Section 78.2 Filing Date]
- § 22:4 [Section 78.21 Applications—No Filing Date]
- § 22:5 [Section 78.22 Applications—Filing Date Before October 1, 1989]
- § 22:6 [Section 78.3 Previous Version of Section 43 Applies]
- § 22:7 [Section 78.4 Applications—Filing Date October 1, 1989 to before October 1, 1996]
- § 22:8 Section 78.4 Commentary
- § 22:9 [Section 78.5 Applications—Filing Date October 1, 1996 to before Coming-into-Force Date]
- § 22:10 [Section 78.51 Abandonment Before Coming-into-Force Date]
- § 22:11 [Section 78.52 Abandonment—Requisition or Notice Before Coming-into-Force Date]
- § 22:12 [Section 78.53 Patents—Filing Date Before October 1, 1989]
- § 22:13 [Section 78.54 Patents—Filing Date October 1, 1989 to Before Coming-into-Force Date]
- § 22:14 [Section 78.55 Application of Section 46—Item 32 of Schedule II to Patent Rules]
- § 22:15 [Section 78.56 Non-Application of Subsection 27.1(4) and Section 73.1]
- § 22:16 [Section 78.57 Reissued Patents]
- § 22:17 [Section 78.58 Regulations]
- § 22:18 Transitional Provisions Not Included in the Patent Act
- § 22:19 [Section 78.6 Payment of Prescribed Fees]
- § 22:20 Section 78.6 Commentary

## **CHAPTER 23. PATENTED OR PROTECTED MEDICINES**

### **I. INTERPRETATION**

- § 23:1 [Section 79 Definitions]
- § 23:2 Section 79 Commentary

### **II. PRICING INFORMATION**

- § 23:3 [Section 80 Pricing Information, Etc., Required by Regulations]

## TABLE OF CONTENTS

- § 23:4 Section 80 Commentary
- § 23:5 [Section 81 Pricing Information, Etc., Required by Board]
- § 23:6 Section 81 Commentary
- § 23:7 [Section 82 Notice of Introductory Price]

### **III. EXCESSIVE PRICES**

- § 23:8 [Section 83 Order Re Excessive Prices]
- § 23:9 Section 83 Commentary
- § 23:10 [Section 84 Compliance]
- § 23:11 [Section 85 Factors to Be Considered]
- § 23:12 Section 85 Commentary
- § 23:13 [Section 86 Hearings to Be Public]
- § 23:14 Section 86 Commentary
- § 23:15 [Section 87 Information, Etc., Privileged]

### **IV. SALES AND EXPENSE INFORMATION**

- § 23:16 [Section 88 Sales and Expense Information, Etc., to Be Provided]
- § 23:17 [Section 89 Report]

### **V. INQUIRIES**

- § 23:18 [Section 90 Inquiries]

### **VI. PATENTED MEDICINE PRICES REVIEW BOARD**

- § 23:19 [Section 91 Establishment]
- § 23:20 [Section 92 Advisory Panel]
- § 23:21 [Section 93 Chairperson and Vice-Chairperson]
- § 23:22 [Section 94 Staff]
- § 23:23 [Section 95 Principal Office]
- § 23:24 [Section 96 General Powers, Etc.]
- § 23:25 Section 96 Commentary
- § 23:26 [Section 97 Proceedings]
- § 23:27 [Section 98 Orders]
- § 23:28 [Section 99 Enforcement of Orders]
- § 23:29 [Section 100 Report of Board]
- § 23:30 [Section 101 Regulations]

### **VII. MEETINGS WITH MINISTER**

- § 23:31 [Section 102 Meetings with Minister]

### **VIII. AGREEMENTS WITH PROVINCES**

- § 23:32 [Section 103 Agreements with Provinces]

## **IX. CASE LAW (SECTIONS 79-103)—PATENTED MEDICINES—REGULATIONS**

§ 23:33 Patented Medicines Case Law (Sections 79-103)

## **CHAPTER 24. SUPPLEMENTARY PROTECTION FOR INVENTIONS—MEDICINAL INGREDIENTS**

### **I. INTERPRETATION**

§ 24:1 [Section 104 Definitions]  
§ 24:2 General  
§ 24:3 Case Law  
§ 24:4 [Section 105 Interpretation]

### **II. APPLICATION FOR CERTIFICATE OF SUPPLEMENTARY PROTECTION**

§ 24:5 [Section 106 Application]  
§ 24:6 General  
§ 24:7 Case Law  
§ 24:8 [Section 107 Information to Be Provided]  
§ 24:9 [Section 108 Order of Priority—Same Authorization for Sale]  
§ 24:10 [Section 109 Applications with Same Authorization for Sale and Priority]  
§ 24:11 [Section 110 Declaration of Non-Compliance]  
§ 24:12 [Section 111 Expiry of Pending Applications]  
§ 24:13 [Section 112 Withdrawal]

### **III. CERTIFICATE OF SUPPLEMENTARY PROTECTION**

§ 24:14 [Section 113 Issue of Certificate]  
§ 24:15 Section 113 Commentary  
§ 24:16 [Section 114 Contents of Certificate]  
§ 24:17 Section 114 Commentary  
§ 24:18 [Section 115 Scope of Supplementary Protection]  
§ 24:19 Section 115 Commentary  
§ 24:20 [Section 116 Validity]  
§ 24:21 Section 116 Commentary  
§ 24:22 [Section 117 Revocation of Certificate]

### **IV. TRANSFER**

§ 24:23 [Section 118 Transfer of Patent]

## TABLE OF CONTENTS

### **V. ADMINISTRATIVE MATTERS**

- § 24:24 [Section 119 Applications, Fees and Documents]
- § 24:25 [Section 120 Inspection by Public]
- § 24:26 [Section 121 Copy in Case of Loss or Destruction]
- § 24:27 [Section 122 Issuance of Patent under Section 47]

### **VI. USE OF CERTIFICATES OF SUPPLEMENTARY PROTECTION BY GOVERNMENT**

- § 24:28 [Section 123 Application]

### **VII. LEGAL PROCEEDINGS IN RESPECT OF CERTIFICATES OF SUPPLEMENTARY PROTECTION**

- § 24:29 [Section 123.1 Admissible in Evidence]

### **VIII. INFRINGEMENT AND IMPEACHMENT**

- § 24:30 [Section 124 Action for Infringement]
- § 24:31 Section 124 Commentary
- § 24:32 [Section 125 Impeachment]
- § 24:33 [Section 126 Judgment Voiding Certificate or Claim]

### **IX. ABUSE OF RIGHTS**

- § 24:34 [Section 127 Abuse of Patent Rights]
- § 24:35 Section 127 Commentary
- § 24:36 [Section 128 Provisions That Apply]

### **X. GENERAL**

- § 24:37 [Section 129 Electronic Form and Means]
- § 24:38 [Section 130 Certified Copies as Evidence]
- § 24:39 [Section 131 Costs of Proceedings]
- § 24:40 [Section 132 Time Limit Deemed Extended]
- § 24:41 [Section 133 Service Fees Act]
- § 24:42 [Section 134 Regulations]
- § 24:43 Section 134 Commentary

## **CHAPTER 25. SCHEDULES TO THE PATENT ACT**

- § 25:1 Introduction
- § 25:2 Schedule 1

- § 25:3 Schedule 2
- § 25:4 Schedule 3
- § 25:5 Schedule 4

## **CHAPTER 26. REPEALED PROVISIONS**

- § 26:1 Introduction
- § 26:2 Definitions(R2)
- § 26:3 Clerical Errors(R8)
- § 26:4 Inspection by the Public(R10)
- § 26:5 Rules and Regulations(R12)
- § 26:6 Patent Attorneys(R15)
- § 26:7 Appeals from Commissioner(R18)
- § 26:8 Government Use of Inventions(R19)
- § 26:9 Communication to Atomic Energy Control Board(R22)
- § 26:10 Marking(R24)
- § 26:11 Annual Report(R26)
- § 26:12 Novelty—Grace Period(R27)
- § 26:13 Self-Priority
- § 26:14 Section 27(1.5)
- § 26:15 Unpatentable Subject-Matter
- § 26:16 Priority—Statutory Bar(R28)
- § 26:17 Non-resident Applicants(R29)
- § 26:18 Completion(R30)
- § 26:19 Particulars Required(R33)
- § 26:20 Specification(R34)
- § 26:21 Filing(R34.1)
- § 26:22 Examination of Patent Applications(R35)
- § 26:23 Divisional Applications(R36)
- § 26:24 Drawings(R37)
- § 26:25 Dangerous Substances(R38)
- § 26:26 Compulsory Licensing—Pharmaceuticals(R39)
- § 26:27 Patented Medicine Prices Review Board(R39.1 to R39.26)
- § 26:28 Conflict between Pending Application and Granted Patent(R41)
- § 26:29 Appeal from Refusal of Patent Application(R42)
- § 26:30 Conflict between Co-Pending Applications(R43)
- § 26:31 Grant of Patents(R43)
- § 26:32 Term(R44)
- § 26:33 Maintenance Fees—Patents(R46)
- § 26:34 Disclaimer(R48)
- § 26:35 Re-Examination(R48.1)
- § 26:36 Assignment(R49 to R50)



## TABLE OF CONTENTS

|         |  |
|---------|--|
| § 26:37 | Infringement—Damages(R55)  |
| § 26:38 | —Reverse Burden of Proof(R55.1)  |
| § 26:39 | —Exceptions to Infringement—Stockpiling for Sale<br>After Expiry of Patent(R55.2)                  |
| § 26:40 | Transitional Provision   |
| § 26:41 | Prior User’s Right—Exemption from<br>Infringement(R56)   |
| § 26:42 | Setting Aside Prior Conflicting Patent(R61)  |
| § 26:43 | Certificate of Judgment(R62)   |
| § 26:44 | Abuse of Patent Rights—Working in Canada(R64)  |
| § 26:45 | Abuse of Exclusive Rights(R65)   |
| § 26:46 | Caveats(R72)   |
| § 26:47 | Forfeiture and Restoration of Applications(R73)  |
| § 26:48 | Marking—Penalty(R74)   |
| § 26:49 | Transitional(R77)  |
| § 26:50 | Patent Applications Filed Before October 1,<br>1989(R78.1)   |
| § 26:51 | Patents Issued on or After October 1, 1989 on the<br>Basis of Previously Filed Applications(R78.2) |
| § 26:52 | Patent Applications Filed on or After October 1,<br>1989(R78.4)                                    |
| § 26:53 | Coming into Force(R78.5)   |

## APPENDICES

Appendix A. Patent Rules [Repealed], SOR/96-423

Appendix B. Patent Rules, SOR/2019-251

Appendix C. Public Servants Inventions Act

### **Appendix D. Patented Medicines (Notice of Compliance) Regulations**

Appendix D1. Patented Medicines (Notice of Compliance)  
Regulations, SOR/93-133

Appendix D2. P.C. 2011-453 March 25, 2011 and  
Regulatory Impact Analysis Statement

Appendix D3. P.C. 2010-1249 October 7, 201 and  
Regulatory Impact Analysis Statement

Appendix D4. P.C. 2008-1090 June 12, 2008 and  
Regulatory Impact Analysis Statement

Appendix D5. P.C. 2006-1077 October 5, 2006 and  
Regulatory Impact Analysis Statement

Appendix D6. P.C. 1998-366 12 March, 1998 and  
Regulatory Impact Analysis Statement

Appendix D7. Regulatory Impact Analysis Statement,  
SOR/93-133

- Appendix D8. Regulatory Impact Analysis Statement,  
SOR/2017-166
- Appendix D9. Guidance Document: Patented Medicines  
(Notice of Compliance) Regulations
- Appendix D10. Case and Trial Management Guidelines for  
Complex Proceedings and Proceedings  
under the *PM(NOC) Regulations*
- Appendix E. Use of Patented Products for International  
Humanitarian Purposes Regulations
- Appendix F. Patented Medicines Regulations
- Appendix G. Certificate of Supplementary Protection  
Regulations
- Appendix H. Patented Medicine Prices Review Board  
Rules of Practice and Procedure
- Appendix I. Patented Medicine Prices Review Board  
Compendium of Policies, Guidelines and  
Procedures

**Appendix J. Patented Medicine Prices Review Board  
Guidelines 2019**

- Appendix J1. Draft Guidelines Consultation 2019
- Appendix J2. Patented Medicine Prices Review Board  
Guidelines 2019
- Appendix K. Canadian Intellectual Property Office  
Practice Notices

**Appendix L. Quantum Tables**

- Appendix L1. Quantum Table—Remedies for Patent  
Infringement

## Volume 3

- Appendix L1.** Quantum Table—Remedies for Patent  
Infringement (Continued)
- Appendix L2. Quantum Table Damages Pursuant to  
Section 8 of the Patented Medicines  
(Notice of Compliance) Regulations
- Appendix L.50. College of Patent Agents and Trademark  
Agents
- Appendix M. Patent Law Treaty
- Appendix N. Patent Cooperation Treaty
- Appendix O. Regulations under the Patent Cooperation  
Treaty

## TABLE OF CONTENTS

|                                     |   |
|-------------------------------------|---|
| Appendix O.1.                       | Administrative Instructions Under the Patent Cooperation Treaty |
| Appendix P.                         | PCT Applicant's Guide (International Phase)                     |
| Appendix Q.                         | PCT Applicant's Guide (National Chapter—CA)                     |
| Appendix R.                         | Current Developments  |
| Appendix S.                         | Canada-United States-Mexico Agreement (CUSMA)                   |
| Appendix T.                         | Legal Memos   |
| Appendix U.                         | Manual of Patent Office Practice                                |
| <b>Appendix V. CIPO Patent Fees</b> |   |
| Appendix V1.                        | Patent Fees   |
| Appendix V2.                        | Methods of Payment Accepted                                     |
| <b>Table of Cases</b>               |   |
| <b>Index</b>                        |   |

